The Vaccine King Who Tried to Sell His Castle (and Got Locked Out Instead)

Think of it like a football coach who tries to trade the franchise quarterback. Even if the deal falls through, the locker room remembers. Chaplin backed a sale that key shareholders rejected. That's hard to walk back.

The company has launched a formal CEO search, with Chaplin staying on through the transition. It's orderly, not panicked. But the strategic vacuum is real.

A Company Worth Fighting Over

To understand why ATP fought so hard to block the sale, you need to look at what Bavarian Nordic actually has.

The company's crown jewel is Jynneos (also marketed as Imvanex and Imvamune), a leading approved non-replicating smallpox and mpox vaccine. When mpox surged globally, governments came calling. In 2025, Bavarian Nordic's Public Preparedness division (essentially the Jynneos franchise) pulled in DKK 3.1 billion in revenue, more than DKK 1 billion above its normal base business.

That's not a one-trick story, either. The company has built a diversified travel vaccine portfolio covering rabies, tick-borne encephalitis, and other diseases. And it recently launched Vimkunya, a single-dose chikungunya vaccine approved by the FDA in early 2025. A distribution deal with Eurofarma targets a Brazil launch in the second half of 2027, opening up endemic markets across Latin America.

There's also a next-generation influenza program supported by an EU pre-commercial procurement initiative and an equine encephalitis vaccine candidate in Phase 2 development, funded by the U.S. government.

ATP's logic starts to make sense: why sell all of this for DKK 250 a share?

The Normalization Problem

Of course, bulls don't get the whole story. The mpox-driven bonanza is fading. Bavarian Nordic is guiding for DKK 1.8 to 2.0 billion in Public Preparedness revenue for 2026, a roughly 35-40% decline from last year. The company itself calls 2026 "a more normalized year without the impact from ongoing outbreaks."

Total revenue guidance for 2026 sits at DKK 5.0 to 5.2 billion, down from approximately DKK 6.2 billion in 2025. EBITDA margins should hold around 25%, which is solid but not spectacular. The stock currently trades near DKK 185 to 198, below Morningstar's quantitative (model-driven) fair value estimate of DKK 226.72, tagged with "High" uncertainty.

So the question facing Bavarian Nordic's next CEO is genuinely tricky: how do you maintain growth when your biggest revenue driver is cooling off?

Ripe for Round Two?

The failed PE bid, a leadership shakeup, and a stock trading below estimated fair value create a textbook setup for renewed M&A interest. Not tomorrow, necessarily, but the ingredients are all there.

Consider who might come shopping. A large vaccine player could want Bavarian Nordic's government relationships and biodefense infrastructure (think BARDA in the U.S., HERA in Europe). A big pharma company looking to diversify beyond crowded flu and pediatric markets might see the travel health franchise as a plug-and-play revenue stream. And private equity already showed its hand once; a sweetened offer at a better time (say, after a new CEO settles in and the stock stays depressed) isn't hard to imagine.

On the other hand, Bavarian Nordic has been explicit about wanting to be the acquirer, not the acquired. Management has talked about using its commercial infrastructure to bolt on more niche vaccine assets. Key partnerships with Valneva and Dynavax are rolling off in 2025 and 2026, freeing up bandwidth (and creating a need) for new products.

What Comes Next

The CEO search will be the single most important signal investors watch over the coming months. Hire a dealmaker, and the market will read it as preparation for a sale. Hire an operator focused on organic growth, and it signals independence. Hire someone with deep government and biodefense connections, and it tells you the mpox/preparedness franchise remains the priority.

Bavarian Nordic isn't in crisis. It's profitable, diversified (by vaccine standards), and sitting on roughly DKK 1.3 billion in already-contracted 2026 preparedness revenue. But the company is at an inflection point, caught between shareholders who believe it's worth more than anyone has offered and a market that's watching the mpox tailwind fade.

The castle isn't for sale anymore. The question is whether the next person running it will fortify the walls or quietly leave the drawbridge down.

IQVIA Just Bought the Part of Charles River That Sees the Future

IQVIA is paying $145 million for Charles River's European discovery labs and AI platform, giving it something it's never had: real drug discovery muscle from day one. The deal bets big on non-animal testing methods and AI-driven chemistry at a moment when regulators are rewriting the rules of preclinical research.